Oncimmune

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and be applied to a wide range of solid tumour types. In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since over 125,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
Company Growth (employees)
Type
Private
HQ
Nottingham, GB
Founded
2006
Size (employees)
33 (est)
Oncimmune was founded in 2006 and is headquartered in Nottingham, GB

Oncimmune Office Locations

Oncimmune has offices in Nottingham, De Soto
Nottingham, GB
De Soto, US

Oncimmune Metrics

Oncimmune Summary

Founding Date

2006

Total Funding

$15 m

Latest funding size

$15 m

Time since last funding

2 months

Investors

We estimate that Oncimmune's latest funding round in January 2017 was $15 m. In total, Oncimmune has raised $15 m

Oncimmune Financials

We estimate that Oncimmune's revenue is £1.5 m in FY, 2013 which is a 45.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

£1.5 m£1.1 m£1.3 m£303 k

Revenue growth, %

(31.1%)27.3%(77.5%)

Cost of sales

£136.3 k£140.5 k£2.9 k

Gross profit

£1.4 m£916.4 k£1.3 m

Gross profit Margin, %

91.1%86.7%99.8%

Operating expense total

£4.5 m£3.7 m£2.7 m
We estimate that Oncimmune's current employees are approximately 10% female and 90% male.

Oncimmune Online Presence

Oncimmune Company Life

You may also be interested in